Whether treating patients with complex cancers or those with benign tumors, I am dedicated to providing each patient with the absolute best possible outcome. Attaining this high standard requires that our team operate at the very leading edge of medicine while still providing patients with the same care we would provide members of our very own family.

Biography 

Jeffrey J. Houlton, M.D., joined the department in 2014. He is currently an assistant professor and is also a member of the Head & Neck Surgery Division.

Dr. Houlton was raised in Houston, Texas, and graduated medical school at the University of Texas Medical Branch with high honors. In medical school he was inducted into the prestigious Alpha Omega Alpha Honor Society. He underwent residency training in otolaryngology - head and neck surgery at the University of Cincinnati where he developed special interest in the treatment of head and neck cancer patients and their complex reconstructive needs. This led him to pursue advanced training in the field of head and neck oncology and reconstructive surgery at the Medical University of South Carolina where he underwent fellowship training.

Dr. Houlton has been married to his wife Crystal for five years and has two young sons, Caleb and Everett.

Overview 

Undergraduate Education: Texas A&M University, 2000

Medical School: University of Texas Medical Branch, 2004

Internship: University of Cincinnati Department of Otolaryngology, 2009

Residency: University of Cincinnati Department of Otolaryngology, 2013

Fellowship: Head and Neck Surgical Oncology and Microvascular Reconstruction, Medical University of South Carolina, 2014

Board Certification: Otolaryngology, 2014

Memberships: American Head and Neck Society, American Academy of Otolaryngology, Alpha Omega Alpha Honor Society

Awards and honors 

2018, 2017: Seattle Metropolitan Magazine Top Doctors
2018: National Cancer Institute Investigator
2018: Engineering in Health - Faculty Mentor Award 
2015: Distinguished Service for Model AAO-HNS Committee
2017-present: Consultant, AAO-HNS Microvascular Committee
2015-present: Washington State Representative, National Young Physicians Section of the AMA
2013-2017: American Academy of Otolaryngology Microvascular Committee
2013-2015: American Academy of Otolaryngology Endocrine Surgery Committee
2011: American Laryngo9logical Association Research Award
2007: Alpha Omega Alpha Honor Society

 

Academic interests 

CLINICAL INTERESTS

Dr. Houlton has clinical expertise in the treatment of cancers of the head and neck, as well as advanced microvascular reconstruction. He has special interest in the area of thyroid and parathyroid surgery, as well as salivary gland disease (including sialoendsocopy).

RESEARCH FOCUS

Dr. Houlton is passionate about clinical outcomes research related to microvascular reconstructive surgery, head and neck cancer treatment, and thyroid/parathyroid surgery.

 

Recent Publications

Cannon RB, Houlton JJ, Patel S, Raju S, Noble A, Futran ND, Parvathaneni U, Méndez E. Patterns of cervical node positivity, regional failure rates, and fistula rates for HPV+ oropharyngeal squamous cell carcinoma treated with transoral robotic surgery (TORS)., Oral Oncol. 2018 Nov; 86296-300

Defining Optimal Treatment Times in Head and Neck Cancer Care: What Are We Waiting For?, JAMA Otolaryngol Head Neck Surg 2018 Nov

Gobillot TA, Kaka AS, Patel SA, Rodriguez C, Cannon RB, Futran ND, Houlton JJ. Treatment of Tonsillar Carcinoma following Nononcologic Tonsillectomy: Efficacy of Transoral Robotic Revision Tonsillectomy., Otolaryngol Head Neck Surg 2018 Oct194599818802185

Cannon RB, Shepherd HM, McCrary H, Carpenter PS, Buchmann LO, Hunt JP, Houlton JJ, Monroe MM. Association of the Patient Protection and Affordable Care Act With Insurance Coverage for Head and Neck Cancer in the SEER Database., JAMA Otolaryngol Head Neck Surg 2018 Nov; 144(11):1052-1057

Torrecillas V, Shepherd HM, Francis S, Buchmann LO, Monroe MM, Lloyd S, Cannon D, Hitchcock YJ, Weis JR, Hunt JP, Houlton JJ, Cannon RB. Adjuvant radiation for T1-2N1 oral cavity cancer survival outcomes and utilization treatment trends: Analysis of the SEER database., Oral Oncol. 2018 Oct; 851-7